RECURSION PHARMACEUTICALS, INC. (RXRX) 2025年第一季度财报(10-Q)「NASDAQ」.pdf

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-Q(Mark One)QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31,2025or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT O

2、F 1934For the transition period from to Commission File Number:001-40323RECURSION PHARMACEUTICALS,INC.(Exact name of registrant as specified in its charter)Delaware 46-4099738(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)41 S Rio Grande StreetSalt L

3、ake City,UT 84101(Address of principal executive offices)(Zip code)(385)269-0203(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading symbol(s)Name of each exchange on which registeredClass A Common Stock,par value$0.00

4、001RXRXNasdaq Global Select MarketIndicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the SecuritiesExchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was required to file suchreports),and

5、(2)has been subject to such filing requirements for the past 90 days.Yes x No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during the preceding 12 months(o

6、r for such shorter periodthat the registrant was required to submit such files).Yes x No Indicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-accelerated filer,a smallerreporting company,or an emerging growth company.See the definitions of“large accel